Companies/INNOCAN PHARMA Corp

Company profile

INNOCAN PHARMA Corp

OTC: INNPF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Calgary, ABReports USD

#512 of 1,394 Healthcare companies by revenue32nd-percentile growth

EA Score

59C

FH 68DQ —GM 44SS 33

v0.1 · 45/100 weight · provisional

↑ 3-yr revenue growth, balance-sheet leverage · ↓ growth stability, listing tenure

Methodology →

Revenue TTM

$25.2M

Rev growth YoY (TTM)

-17.3%

Net income (FY)

-$1.1M

Employees

Market cap

$7.2M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$26.6M$26.6M2025

Net income-$1.1M-$1.1M2025

Operating income-$1.3M-$1.3M2025

Total assets$10.5M$10.5M2025

Liabilities$2.3M$2.3M2025

Equity$5.6M$5.6M2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

$8.0k

FY20

$196.0k

FY21

$2.6M

FY22

$13.7M

FY23

$29.4M

FY24

$26.6M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

INNOCAN PHARMA Corp booked $26.6M in FY2025 revenue, contracting 9.6% year over year — slower than 68% of Healthcare companies we track, at a -4.2% net margin.

Peers · Healthcare

cbdMD, Inc.50D Comprehensive Healthcare Systems, Inc.42D Curanex Pharmaceuticals Inc Common Stock——BioCorRx Inc.44D

Key facts

CEOIris Bincovich

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersCalgary, AB

ExchangeOTC: INNPF

Employees11

IPO date2020-11-27

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.